GSE199107 tryptophan 4 v 5 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE199107_tryptophan_4_v_5_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE199107_tryptophan_4_v_5_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE199107_tryptophan_4_v_5_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE199107_tryptophan_4_v_5_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

non-coding RNA activated by DNA damage

Gene

H2A clustered histone 4

Gene

LOXL1 antisense RNA 1

Gene

small nucleolar RNA host gene 33

Gene

MIR31 host gene

Gene

nicotinamide phosphoribosyltransferase pseudogene 1

Gene

long intergenic non-protein coding RNA 2577

Gene

prostate cancer associated transcript 7

Gene

long intergenic non-protein coding RNA 1605

Gene

long intergenic non-protein coding RNA 2609

  • Gene

    non-coding RNA activated by DNA damage


  • Gene

    H2A clustered histone 4


  • Gene

    LOXL1 antisense RNA 1


  • Gene

    small nucleolar RNA host gene 33



  • Gene

    nicotinamide phosphoribosyltransferase pseudogene 1


  • Gene

    long intergenic non-protein coding RNA 2577


  • Gene

    prostate cancer associated transcript 7


  • Gene

    long intergenic non-protein coding RNA 1605


  • Gene

    long intergenic non-protein coding RNA 2609

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.